The initiation of coverage realized by ODDO-BHF on July 20, 2021, with a study entitled “First approval and launch expected in 2022”, strengthens the visibility of the MedinCell share among French and international institutional investors.
This coverage comes in addition to those already carried out by the brokerage firms Bryan Garnier and Kepler Cheuvreux.